Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies

Barwon Health60 enrolled

Overview

The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with hyperthyroidism due to Graves' disease. The other aim of this study is to determine the incidence of the various ophthalmopathy subtypes and the utility of orbital antibodies in the diagnosis, classification and monitoring of patients with thyroid-associated ophthalmopathy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Graves' Ophthalmopathy

Interventions

Carbimazole, radio-active iodine (I131)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Graves' disease diagnosed in the last 3 months, regardless of the presence of ophthalmopathy Exclusion Criteria: * Pre-existing eye disease: e.g. orbital surgery, orbital irradiation or significant loss of vision * Age \< 18 years * Inability to consent to participation in the study * Pregnancy * History of radio-active iodine therapy

Locations (1)

Barwon Health - The Geelong Hospital

Geelong, Victoria, Australia

Outcomes

Primary Outcomes

Onset or progression of ophthalmopathy following radio-active iodine therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.